Viridian Therapeutics Q2 2021 Earnings Report
Key Takeaways
Viridian Therapeutics reported $109.3 million in cash, cash equivalents and short-term investments as of June 30, 2021. The company's net loss was $18.0 million for the second quarter of 2021.
Completed a successful pre-IND meeting with the FDA for VRDN-001 for Thyroid Eye Disease treatment.
On track to submit IND filings for VRDN-001 and VRDN-002 to the FDA in Q4 2021.
First VRDN-001 clinical trial data has potential to show rapid reduction in proptosis.
Strengthened management team with appointments of Kristian Humer as CFO and CBO, and Deepa Rajagopalan, M.D. as SVP of New Product and Portfolio Development.
Viridian Therapeutics
Viridian Therapeutics
Forward Guidance
Viridian Therapeutics believes that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2024.